Copyright Reports & Markets. All rights reserved.

Global AT1 Receptor Antagonists Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 AT1 Receptor Antagonists Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global AT1 Receptor Antagonists Market Size Growth Rate by Product
      • 1.4.2 Valsartan
      • 1.4.3 Telmisartan
      • 1.4.4 Losartan
      • 1.4.5 Irbesartan
      • 1.4.6 Azilsartan
      • 1.4.7 Olmesartan
    • 1.5 Market by End User
      • 1.5.1 Global AT1 Receptor Antagonists Market Size Growth Rate by End User
      • 1.5.2 Hypertension
      • 1.5.3 Cardiovascular Diseases
      • 1.5.4 Kidney Diseases
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global AT1 Receptor Antagonists Market Size
      • 2.1.1 Global AT1 Receptor Antagonists Revenue 2014-2025
      • 2.1.2 Global AT1 Receptor Antagonists Sales 2014-2025
    • 2.2 AT1 Receptor Antagonists Growth Rate by Regions
      • 2.2.1 Global AT1 Receptor Antagonists Sales by Regions
      • 2.2.2 Global AT1 Receptor Antagonists Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 AT1 Receptor Antagonists Sales by Manufacturers
      • 3.1.1 AT1 Receptor Antagonists Sales by Manufacturers
      • 3.1.2 AT1 Receptor Antagonists Sales Market Share by Manufacturers
      • 3.1.3 Global AT1 Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
    • 3.2 AT1 Receptor Antagonists Revenue by Manufacturers
      • 3.2.1 AT1 Receptor Antagonists Revenue by Manufacturers (2014-2019)
      • 3.2.2 AT1 Receptor Antagonists Revenue Share by Manufacturers (2014-2019)
    • 3.3 AT1 Receptor Antagonists Price by Manufacturers
    • 3.4 AT1 Receptor Antagonists Manufacturing Base Distribution, Product Types
      • 3.4.1 AT1 Receptor Antagonists Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers AT1 Receptor Antagonists Product Type
      • 3.4.3 Date of International Manufacturers Enter into AT1 Receptor Antagonists Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global AT1 Receptor Antagonists Sales by Product
    • 4.2 Global AT1 Receptor Antagonists Revenue by Product
    • 4.3 AT1 Receptor Antagonists Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global AT1 Receptor Antagonists Breakdown Data by End User

    6 North America

    • 6.1 North America AT1 Receptor Antagonists by Countries
      • 6.1.1 North America AT1 Receptor Antagonists Sales by Countries
      • 6.1.2 North America AT1 Receptor Antagonists Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America AT1 Receptor Antagonists by Product
    • 6.3 North America AT1 Receptor Antagonists by End User

    7 Europe

    • 7.1 Europe AT1 Receptor Antagonists by Countries
      • 7.1.1 Europe AT1 Receptor Antagonists Sales by Countries
      • 7.1.2 Europe AT1 Receptor Antagonists Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe AT1 Receptor Antagonists by Product
    • 7.3 Europe AT1 Receptor Antagonists by End User

    8 Asia Pacific

    • 8.1 Asia Pacific AT1 Receptor Antagonists by Countries
      • 8.1.1 Asia Pacific AT1 Receptor Antagonists Sales by Countries
      • 8.1.2 Asia Pacific AT1 Receptor Antagonists Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific AT1 Receptor Antagonists by Product
    • 8.3 Asia Pacific AT1 Receptor Antagonists by End User

    9 Central & South America

    • 9.1 Central & South America AT1 Receptor Antagonists by Countries
      • 9.1.1 Central & South America AT1 Receptor Antagonists Sales by Countries
      • 9.1.2 Central & South America AT1 Receptor Antagonists Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America AT1 Receptor Antagonists by Product
    • 9.3 Central & South America AT1 Receptor Antagonists by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa AT1 Receptor Antagonists by Countries
      • 10.1.1 Middle East and Africa AT1 Receptor Antagonists Sales by Countries
      • 10.1.2 Middle East and Africa AT1 Receptor Antagonists Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa AT1 Receptor Antagonists by Product
    • 10.3 Middle East and Africa AT1 Receptor Antagonists by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer AT1 Receptor Antagonists Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Novartis
      • 11.2.1 Novartis Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Novartis AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Novartis AT1 Receptor Antagonists Products Offered
      • 11.2.5 Novartis Recent Development
    • 11.3 Merck
      • 11.3.1 Merck Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck AT1 Receptor Antagonists Products Offered
      • 11.3.5 Merck Recent Development
    • 11.4 Astra Zeneca
      • 11.4.1 Astra Zeneca Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Astra Zeneca AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Astra Zeneca AT1 Receptor Antagonists Products Offered
      • 11.4.5 Astra Zeneca Recent Development
    • 11.5 Jhonson and Johnson
      • 11.5.1 Jhonson and Johnson Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Jhonson and Johnson AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Jhonson and Johnson AT1 Receptor Antagonists Products Offered
      • 11.5.5 Jhonson and Johnson Recent Development
    • 11.6 Eli Lilly
      • 11.6.1 Eli Lilly Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Eli Lilly AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Eli Lilly AT1 Receptor Antagonists Products Offered
      • 11.6.5 Eli Lilly Recent Development
    • 11.7 Sanofi
      • 11.7.1 Sanofi Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sanofi AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sanofi AT1 Receptor Antagonists Products Offered
      • 11.7.5 Sanofi Recent Development
    • 11.8 Bristol-Myers Squibb
      • 11.8.1 Bristol-Myers Squibb Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Bristol-Myers Squibb AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Bristol-Myers Squibb AT1 Receptor Antagonists Products Offered
      • 11.8.5 Bristol-Myers Squibb Recent Development
    • 11.9 Bayer
      • 11.9.1 Bayer Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Bayer AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Bayer AT1 Receptor Antagonists Products Offered
      • 11.9.5 Bayer Recent Development
    • 11.10 GSK
      • 11.10.1 GSK Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 GSK AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 GSK AT1 Receptor Antagonists Products Offered
      • 11.10.5 GSK Recent Development
    • 11.11 Teva Pharmaceutical

    12 Future Forecast

    • 12.1 AT1 Receptor Antagonists Market Forecast by Regions
      • 12.1.1 Global AT1 Receptor Antagonists Sales Forecast by Regions 2019-2025
      • 12.1.2 Global AT1 Receptor Antagonists Revenue Forecast by Regions 2019-2025
    • 12.2 AT1 Receptor Antagonists Market Forecast by Product
      • 12.2.1 Global AT1 Receptor Antagonists Sales Forecast by Product 2019-2025
      • 12.2.2 Global AT1 Receptor Antagonists Revenue Forecast by Product 2019-2025
    • 12.3 AT1 Receptor Antagonists Market Forecast by End User
    • 12.4 North America AT1 Receptor Antagonists Forecast
    • 12.5 Europe AT1 Receptor Antagonists Forecast
    • 12.6 Asia Pacific AT1 Receptor Antagonists Forecast
    • 12.7 Central & South America AT1 Receptor Antagonists Forecast
    • 12.8 Middle East and Africa AT1 Receptor Antagonists Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 AT1 Receptor Antagonists Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      AT1 receptor antagonists are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
      The global AT1 Receptor Antagonists market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the AT1 Receptor Antagonists market based on company, product type, end user and key regions.

      This report studies the global market size of AT1 Receptor Antagonists in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of AT1 Receptor Antagonists in these regions.
      This research report categorizes the global AT1 Receptor Antagonists market by top players/brands, region, type and end user. This report also studies the global AT1 Receptor Antagonists market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Pfizer
      Novartis
      Merck
      Astra Zeneca
      Jhonson and Johnson
      Eli Lilly
      Sanofi
      Bristol-Myers Squibb
      Bayer
      GSK
      Teva Pharmaceutical

      Market size by Product
      Valsartan
      Telmisartan
      Losartan
      Irbesartan
      Azilsartan
      Olmesartan
      Market size by End User
      Hypertension
      Cardiovascular Diseases
      Kidney Diseases
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global AT1 Receptor Antagonists market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of AT1 Receptor Antagonists market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global AT1 Receptor Antagonists companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of AT1 Receptor Antagonists submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of AT1 Receptor Antagonists are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of AT1 Receptor Antagonists market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now